TOP TIERMARKET NEWSWIRE
News & sentiment

Evommune, Inc. (EVMN) — News & AI sentiment

Evommune, Inc. (EVMN) news roundup. 7 stories aggregated over the last 30 days. Average 30-day sentiment is 58.7/100. No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →
24h stories
0
7d stories
0
30d stories
7
avg sentiment 58.7/100
Insider net (90d)
$0
0 buys · 0 sells
Congress (90d)
0
0 buys · 0 sells

EVMN news in the last 24 hours, 7 days, 30 days and 90 days

How much EVMN coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time windowEVMN storiesAvg AI sentimentRead
Last 24 hours0—no coverage
Last 7 days0—no coverage
Last 30 days758.7/100EVMN headlines →
Last 90 days3944.5/100EVMN headlines →

Latest stories on EVMN

Oct 20
UBS initiates Evommune stock coverage with neutral rating on AD potential
Investing.com Analyst Ratings50 · neutralanalyst
Oct 12
Evommune initiated with a Neutral at UBS
The Fly50 · neutralanalyst
Oct 11
Oct 1
Oct 1
Evommune, Inc. (EVMN) files 8-K
SEC 8-K50 · neutralgeneral
Oct 1
Oct 1
Evommune, Inc. (EVMN) files 8-K
SEC 8-K50 · neutralgeneral
Sep 23
Sep 23
Sep 22
Cantor Fitzgerald reiterates Evommune stock rating at Overweight
Investing.com Analyst Ratings56 · neutralanalyst
Sep 18
Sep 16
Evommune, Inc. (EVMN) files 8-K
SEC 8-K50 · neutralgeneral
Sep 15
Sep 9
Stifel reiterates Evommune stock rating after phase 2b trial miss
Investing.com Analyst Ratings42 · neutralanalyst
Sep 9
Sep 9
RBC cuts Evommune stock price target on drug trial setback
Investing.com Analyst Ratings32 · bearishanalyst
Sep 9
Sep 9
Sep 9
Evommune stock maintains Buy rating despite trial setback
Investing.com Analyst Ratings48 · neutralanalyst
Sep 9
Why is Evommune stock sliding 13% today?
Investing.com Markets34 · bearishgeneral
Sep 9
Sep 9
Why is Evommune stock tumbling today?
Investing.com Markets34 · bearishgeneral
Sep 9
Why Is EVMN Stock Down 13% After-Hours?
Stocktwits News22 · bearishearnings
Sep 8
Sep 8
Open EVMN in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →